Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2025 11:16 ET | Source: Zelluna ASA

Zelluna ASA [ZLNA]: Registration of reverse share split

Oslo, Norway, 31 March, 2025 Reference is made to the stock exchange notice published by the Zelluna ASA (the "Company") on 27 March 2025 with key information concerning a reverse share split in the...
March 27, 2025 10:28 ET | Source: Zelluna ASA

Zelluna ASA [ZLNA]: Key information regarding reverse share split and change of ISIN

Oslo, Norway, 27 March, 2025 Reference is made to the stock exchange notice published on 9 January 2025 regarding an extraordinary general meeting held in Zelluna ASA (the "Company"), where it was...
March 27, 2025 05:21 ET | Source: Zelluna ASA

Zelluna ASA [ZLNA]: Share capital increase registered

Oslo, Norway, 27 March, 2025 Reference is made to the stock exchange notice published on 26 March 2025 regarding the resolution of the board of directors of Zelluna ASA (the "Company") to carry out a...
March 26, 2025 08:55 ET | Source: Zelluna ASA

Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary insider

Oslo, Norway, 26 March, 2025 Reference is made to the stock exchange notice published by Zelluna ASA (the "Company") published on 26 March 2025 regarding the resolution by the Company's board of...
March 26, 2025 08:22 ET | Source: Zelluna ASA

Zelluna ASA [ZLNA]: Share capital increase resolution

Oslo, Norway, 26 March, 2025 Reference is made to the stock exchange notice published on 9 January 2025 regarding an extraordinary general meeting held in Zelluna ASA (the "Company"), where it was...
March 03, 2025 10:46 ET | Source: Zelluna ASA

Zelluna ASA [ZLNA]: The first ever cell therapy company to list on the Oslo Stock Exchange following successful completion of the business combination and private placement

Oslo, Norway, 03 March, 2025 - Zelluna ASA, a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, today announces the...
February 28, 2025 08:45 ET | Source: Ultimovacs ASA

Ultimovacs ASA: Approval and publication of prospectus

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION...
February 13, 2025 11:30 ET | Source: Ultimovacs ASA

Ultimovacs ASA: Cancellation of subsequent repair offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION...
January 31, 2025 01:00 ET | Source: Ultimovacs ASA

Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provides General Business Update

Oslo, January 31, 2025: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its fourth quarter 2024 results...
January 27, 2025 02:48 ET | Source: Ultimovacs ASA

Ultimovacs ASA: Invitation to fourth quarter 2024 results webcast presentation

Oslo, January 27, 2025: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, invites to a webcast presentation of its...